Good comeback for a Friday and a screwed up world. Both Depo and AIS looking good going into the weekend. If all goes well next week could be a fun time.
GLTA & have a great weekend. add2it
AIS and BPAX
Investors will look closely at data from Libigel update presentation Posted on 02/11/11 at 10:00am by Comtex News
(via COMTEX News Network)--
This weekend, biotech investors and the rest of the medical community will get an update on the largest-ever safety study comparing low-dose testosterone treatments to placebo treatment for menopausal women who suffer from Hypoactive Sexual Desire Disorder (HSDD).
Two companies in prime position to benefit from good news associated with this weekend's updated clinical information are BioSante Pharmaceuticals (Nasdaq: BPAX) and their partner, Antares Pharma, Inc. (AMEX: AIS).
Both companies have a large stake in LibiGel- a testosterone gel that is the focus of that Phase III clinical trial and is now clearly the lead product in development for treating female sexual dysfunction. The efficacy trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement.
News 
Market Data 
Discover 
AI
